

DAFTAR PUSTAKA

- [1] “Statistics at a glance, 2022 Top 5 most frequent cancers Number of new cases 408 661 Number of deaths 242 988 Number of prevalent cases (5-year)”.
- [2] Kementerian Kesehatan Republik Indonesia, Panduan Penatalaksanaan Kanker Serviks, Komite Penanggulangan Kanker Nasional, disetujui oleh HOGI, PORI, PERHOMPEDIN, IAPI, PDSRI, PERDOSRI, dan PDGKI, Jakarta, 2022. [Online]. Available: <https://kanker.kemkes.go.id/wp-content/uploads/2023/04/Panduan-Kanker-Serviks2022.pdf>
- [3] Kementerian Kesehatan Republik Indonesia, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/349/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Serviks, Jakarta: Kementerian Kesehatan RI, 2018. [Online]. <https://peraturan.bpk.go.id/Home/Details/112319/keputusan-menkes-hk0107menkes3492018-tahun-2018>
- [4] D. Cibula *dkk.*, “ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*,” *International Journal of Gynecological Cancer*, vol. 33, no. 5, hlm. 649–666, Mei 2023, doi: 10.1136/ijgc-2023-004429.
- [5] Z. Liu *dkk.*, “Imaging-guided brachytherapy for locally advanced cervical cancer: the main process and common techniques,” *Am J Cancer Res*, vol. 10, no. 12, hlm. 4165–4177, 2020, Diakses: 28 Juli 2025. [Daring]. Tersedia pada: www.ajcr.us/
- [6] R. Rangarajan, “Which Has a Superior Dosimetric Profile in Image-guided High-dose-rate Brachytherapy of Cervix - Tandem Ovoid or Tandem Ring Applicator?,” *J Med Phys*, vol. 50, no. 1, hlm. 55–59, Jan 2025, doi: 10.4103/jmp.jmp_171_24.
- [7] R. Rangarajan, “Dosimetric evaluation of image based brachytherapy using tandem ovoid and tandem ring applicators,” *Reports of Practical Oncology and Radiotherapy*, vol. 23, no. 1, hlm. 57–60, Jan 2018, doi: 10.1016/j.rpor.2017.12.006.
- [8] S. B. Gursel, A. Serarslan, A. D. Meydan, N. Okumus, dan T. Yasayacak, “A comparison of tandem ring and tandem ovoid treatment as a curative brachytherapy component for cervical cancer,” *J Contemp Brachytherapy*, vol. 12, no. 2, hlm. 111–117, 2020, doi: 10.5114/jcb.2020.94308.



- [9] M. Serban *dkk.*, “Ring Versus Ovoids and Intracavitary Versus Intracavitary-Interstitial Applicators in Cervical Cancer Brachytherapy: Results From the EMBRACE I Study,” *Int J Radiat Oncol Biol Phys*, vol. 106, no. 5, hlm. 1052–1062, 2020, doi: 10.1016/j.ijrobp.2019.12.019.
- [10] A. Prakash, K. Mandal, N. Pokala, dan G. R. Amanapu, “The Dosimetric Comparison Between Tandem-Ovoid and Tandemring Applicator in Cervical Cancer Brachytherapy,” *Journal of Radiation and Cancer Research*, vol. 13, no. 4, hlm. 242–246, Okt 2022, doi: 10.4103/jrcr.jrcr_35_22.
- [11] F. Biltekin, M. Gultekin, M. T. Yilmaz, dan F. Yildiz, “Dosimetric comparison of two different applicators and rectal retraction methods used in inverse optimization-based intracavitary brachytherapy for cervical cancer,” *J Contemp Brachytherapy*, vol. 12, no. 1, hlm. 35–43, 2020, doi: 10.5114/jcb.2020.92699.
- [12] R. A. Wibowo, B. Haris, C. A. P. Winarya, dan K. Ain, “Distribution of Brachytherapy Doses for Cervical Cancer using Vaginal Cylinder and Ovoid Applicators,” dalam *Journal of Physics: Conference Series*, Institute of Physics Publishing, Des 2018. doi: 10.1088/1742-6596/1120/1/012075.
- [13] B. R. Yashaswini *dkk.*, “Comparison of dosimetric analysis of organs at risk and target volumes for ovoids and cylinders in endometrial carcinoma,” *J Contemp Brachytherapy*, vol. 15, no. 6, hlm. 414–421, 2023, doi: 10.5114/jcb.2023.134171.
- [14] R. dwi Cahyani, N. P. R. Jeniyanthi, dan D. Fikli, “Analisis Dosis Organ Target Dan Organ At Risk Pada Brakhiterapi Kasus Kanker Endometrium Menggunakan Alat Aplikator Silinder Di Instalasi Radioterapi Rsup Persahabatan,” Prepotif : Jurnal Kesehatan Masyarakat. Diakses: 12 Agustus 2025. [Daring]. Tersedia pada: <https://journal.universitaspahlawan.ac.id/index.php/prepotif/article/view/37069/25553>
- [15] F. Walter *dkk.*, “Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results,” *Brachytherapy*, vol. 17, no. 5, hlm. 775–781, Sep 2018, doi: 10.1016/j.brachy.2018.05.009.
- [16] P. Rogowski *dkk.*, “Clinical outcome of combined intracavitary / interstitial brachytherapy using a hybrid applicator in locally advanced cervical cancer,” *Gynecol Oncol*, vol. 166, no. 3, hlm. 576–581, Sep 2022, doi: 10.1016/j.ygyno.2022.06.019.



- [17] “What Is Cervical Cancer? - NCI.” Diakses: 21 Agustus 2025. [Daring]. Tersedia pada: <https://www.cancer.gov/types/cervical>
- [18] “Diagnosis Kanker Serviks | Rumah Sakit Tumor Modern Guangzhou, China.” Diakses: 8 Desember 2025. [Daring]. Tersedia pada: <https://www.moderncancerhospital.co.id/cancer-diagnosis/Diagnosis-Kanker/>
- [19] S. Campos, L. Lee, M. Del Carmen, dan D. Mcmeekin, “Corpus: Epithelial Tumors,” *Principles and Practice of Gynecologic Oncology*, no. 3, hlm. 984–1041, 2017.
- [20] D. Fischerova, F. Frühauf, A. Burgetova, I. S. Haldorsen, E. Gatti, dan D. Cibula, “The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023),” *Cancers (Basel)*, vol. 16, no. 4, hlm. 775, Feb 2024, doi: 10.3390/CANCERS16040775/S1.
- [21] “TNM / FIGO.” Diakses: 15 September 2025. [Daring]. Tersedia pada: <https://screening.iarc.fr/atlasclassiftnm.php>
- [22] “The Radiology Assistant : Cervical Cancer - MR staging.” Diakses: 3 September 2025. [Daring]. Tersedia pada: <https://radiologyassistant.nl/abdomen/unsorted/mr-in-cervical-cancer-1>
- [23] N. Bhatla, D. Aoki, D. N. Sharma, dan R. Sankaranarayanan, “Cancer of the cervix uteri: 2021 update,” *International Journal of Gynecology and Obstetrics*, vol. 155, no. S1, hlm. 28–44, Okt 2021, doi: 10.1002/IJGO.13865.
- [24] N. Bhatla, D. Aoki, D. N. Sharma, dan R. Sankaranarayanan, “Cancer of the cervix uteri,” *International Journal of Gynecology and Obstetrics*, vol. 143, hlm. 22–36, Okt 2018, doi: 10.1002/ijgo.12611.
- [25] G. Suneja *dkk.*, “Task Group/Practice Parameter American Brachytherapy Society: Brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries”, doi: 10.1016/j.brachy.2016.10.007.
- [26] N. Comprehensive Cancer Network, “Cervical Cancer NCCN GUIDELINES FOR PATIENTS.”
- [27] The Royal College of Radiologists, *Radiotherapy Dose Fractionation – Third Edition: Gynaecological Cancers (Cervix Cancer Background)*, edisi ke-3, London: The Royal College of Radiologists, 2019, hlm. 32–39. [Daring].
- [28] R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, dan A. S. Meigooni, “Dosimetry of interstitial brachytherapy sources:



- Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43,” *Med Phys*, vol. 22, no. 2, hlm. 209–234, 1995, doi: 10.1118/1.597458.
- [29] IAEA, “HUMAN HEALTH SERIES No. 30 Implementation of High Dose Rate Brachytherapy in Limited Resource Settings”, Diakses: 13 Oktober 2025. [Daring]. Tersedia pada: <http://www.iaea.org/Publications/index.html>
- [30] A. Shukla *dkk.*, “Dosimetric comparison of ^{60}Co and ^{192}Ir High Dose Rate Source used in brachytherapy treatment of cervical cancer,” *J Cancer Res Ther*, vol. 15, no. 6, hlm. 1212–1215, Okt 2019, doi: 10.4103/JCRT.JCRT_372_19.
- [31] S. L. Richardson *dkk.*, “AAPM Medical Physics Practice Guideline 13.a: HDR Brachytherapy, part A,” *Journal of Applied Clinical Medical Physics*, 2023, doi: 10.1002/acm2.13829..
- [32] A. N. Viswanathan, B. T. Reviewed, B. Erickson, D. Gaffney, W. Small, dan I.-C. Hsu, “American Brachytherapy Society Cervical Cancer Brachytherapy Task Group”.
- [33] “The Transition from 2-D Brachytherapy to 3-D High Dose Rate Brachytherapy”, Diakses: 16 Oktober 2025. [Daring]. Tersedia pada: <http://www.iaea.org/Publications/index.html>
- [34] M. J. Rivard *dkk.*, “Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations,” *Med Phys*, vol. 31, no. 3, hlm. 633–674, 2004, doi: 10.1118/1.1646040.
- [35] M. De Brabandere *dkk.*, “GEC-ESTRO guidelines for commissioning and quality assurance of TG-43 based brachytherapy treatment planning systems,” *Radiotherapy and Oncology*, vol. 210, hlm. 111008, Sep 2025, doi: 10.1016/j.radonc.2025.111008.
- [36] T. P. Hellebust *dkk.*, “Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy,” *Radiotherapy and Oncology*, vol. 96, no. 2, hlm. 153–160, Agu 2010, doi: 10.1016/J.RADONC.2010.06.004.
- [37] D. F. Topcoat, “Applicator Guide,” *Head Neck*, 2007, [Daring]. Tersedia pada: <https://www.elekta.com/dam/jcr:5fd34853-7bf3-48ba-8830-68250797bb39/Brachytherapy-Applicator-Guide.pdf>
- [38] A. Mourya, L. Aggarwal, dan S. Choudhary, “Evolution of brachytherapy applicators for the treatment of cervical cancer,” 1 Oktober 2021, *Wolters Kluwer Medknow Publications*. doi: 10.4103/jmp.jmp_62_21.



- [39] T. B. Miladinović *dkk.*, “Distribution of doses to organs at risk in Cervical Cancer High Dose Rate Brachytherapy using Tandem and Ovoids or Vaginal Cylinder,” hlm. 197–200, 2023, doi: 10.46793/ICCB123.197M.
- [40] H. ALMasri, Y. Kakinohana, T. Toita, T. Ariga, G. Kasuya, dan S. Murayama, “Accuracy of Intracavitary Applicator Reconstruction for Cervix Cancer Brachytherapy,” *SN Compr Clin Med*, vol. 2, no. 2, hlm. 133–139, Feb 2020, doi: 10.1007/s42399-019-00204-z.
- [41] A. A. Khan, A. Vijay, S. Q. Wani, dan M. M. Haq, “Dosimetric analysis of intracavitary brachytherapy applicators: a practical study,” *Radiat Oncol J*, vol. 40, no. 3, hlm. 180–191, 2022, doi: 10.3857/roj.2022.00199.
- [42] International Commission on Radiation Units and Measurements, *Report 89 - Prescribing, recording, and reporting brachytherapy for cancer of the cervix*, vol. 13, no. 1–2. 2016. [Daring]. Tersedia pada: <https://doi.org/10.1093/jicru/ndw042>
- [43] R. Sianturi, “Test Normality As a Condition of Hypothesis Testing,” *Jurnal Pembelajaran Dan Matematika Sigma (Jpms)*, vol. 11, no. 1, hlm. 1–14, 2025.
- [44] “View of ANALISIS KRUSKAL-WALLIS UNTUK MENGETAHUI KONSENTRASI BELAJAR MAHASISWA BERDASARKAN BIDANG MINAT PROGRAM STUDI STATISTIKA FMIPA UNPATTI.” Diakses: 2 Desember 2025. [Daring]. Tersedia pada: <https://ojs3.unpatti.ac.id/index.php/parameter/article/view/2812/2359>
- [45] D. Selpia, M. Fathurrahman, M. Susilawati, N. Pratiwi, dan R. Purnami, “Penerapan Uji Mann-Whitney Dalam Perbandingan Prestasi Akademik Mahasiswa Statistika Universitas,” *Jurnal Eksbar*, vol. 1, no. 2, hlm. 19–28, 2024, [Daring]. Tersedia pada: <https://e-journal.hamzanwadi.ac.id/index.php/eksbar/index>
- [46] A. Chaikh, J. Y. Giraud, E. Perrin, J. P. Bresciani, dan J. Balosso, “The choice of statistical methods for comparisons of dosimetric data in radiotherapy,” *Radiat Oncol*, vol. 9, no. 1, hlm. 205, Sep 2014, doi: 10.1186/1748-717X-9-205.
- [47] E. T. H. Fontham *dkk.*, “Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society,” *CA Cancer J Clin*, vol. 70, no. 5, hlm. 321–346, Sep 2020, doi: 10.3322/CAAC.21628.

